Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres.

Study type:

Study number:

42206693

Type of Stem Cell Treatment:

Autologous

Diseases:

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Short title:

Primary objective:

Key inclusion criteria:

Country:

All EBMT member countries

Principal investigator:

Patrick Hayden

EBMT Study coordinator:

Linda Koster

Study coordinator email:

cmwpebmt@lumc.nl

Reason for processing personal data:

Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.

Categories of personal data collected:

DOB/YOB, gender

Medical data already reported to the EBMT Registry

Recipients who may access the data:

Leiden Study Unit

Statistical Unit

Investigators

3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Article 6 lawful basis for processing personal data:

Article 6.1 (a) - Consent (Collection)

Article 9 basis for processing special category data:

Article 9(2) (a) - Consent (Collection)

Rights available to individuals:

Access

Data portability

Rectification

Objection

Deletion

Is a Data Protection Impact Assessment required?:

DPIA performed for EBMT Registry (WP & NIS Studies)

Retention Schedule (if possible):

at least 5 years after the final report or first publication of study results